Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT06351540
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cannabis Use
  • Cognitive Impairment
  • Impaired Driving

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Cannabis — DRUG
    cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization

Study Details

The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.

Key Dates

Start date
Aug 1, 2026
Status verified
May 2026
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: 0 mg THC
    Inhaled Cannabis - 0 mg THC
  • Experimental: 5 mg THC
    Inhaled cannabis - 5 mg THC
  • Experimental: 30 mg THC
    Inhaled cannabis - 30 mg THC

Primary Outcome Measure

Commission Errors [ Time Frame: pre-administration, post-administration, 2, 4 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins Behavioral Pharmacology Research UnitBaltimoreMaryland21224-

Find similar trials in Baltimore, MD

By research site
Johns Hopkins Behavioral Pharmacology Research Unit· Baltimore, MD

Related Studies